New resistance mechanisms to azole drugs in Aspergillus fumigatus and emergence of antifungal drugs-resistant A. fumigatus atypical strains

References

• Singh N. Trends in the epidemiology of opportunistic fungal infections: predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis 2001; 33: 1692–1696
   PubMed Web of Science ®Google Scholar
• Kontoyiannis DP, Bodey GP. Invasive aspergillosis in : an update. Eur J Clin Microbiol Infect Dis 2002; 21: 161–172
   PubMed Web of Science ®Google Scholar
• Clinical Laboratory Standard Institute. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. M38-A. Wayne, PA. Clinical Laboratory Standard Institute 2002.
   Google Scholar
• Cuenca-Estrella M, Rodriguez-Tudela JL, Mellado E, et al. Comparison of the in vitro activity of voriconazole (UK-109,496), itraconazole and amphotericin B against clinical isolates of Aspergillus fumigatus. J Antimicrob Chemother 1998; 42: 531–533
   PubMed Web of Science ®Google Scholar
• Gomez-Lopez A, Garcia-Effron G, Mellado E, et al. In vitro activities of three licensed antifungal agents against spanish clinical isolates of Aspergillus spp. Antimicrob Agents Chemother 2003; 47: 3085–3088
   PubMed Web of Science ®Google Scholar
• Mosquera J, Denning DW. Azole cross-resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2002; 46: 556–557
   PubMed Web of Science ®Google Scholar
• Denning DW, Radford SA, Oakley KL, et al. Correlation between in-vitro susceptibility testing to itraconazole and in-vivo outcome of Aspergillus fumigatus infection. J Antimicrob Chemother 1997; 40: 401–414
   PubMed Web of Science ®Google Scholar
• Verweij PE, Te Dorsthorst DT, Rijs AJ, et al. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998. J Clin Microbiol 2002; 40: 2648–2650
   PubMed Web of Science ®Google Scholar
• Balajee SA, Weaver M, Imhof A, et al. Aspergillus fumigatus variant with decreased susceptibility to multiple antifungals. Antimicrob Agents Chemother 2004; 48: 1197–1203
   PubMed Web of Science ®Google Scholar
• Balajee SA, Gribskov JL, Hanley E, et al. Aspergillus lentulus sp. nov., a new sibling species of A. fumigatus. Eukaryot Cell 2005; 4: 625–632
   PubMedGoogle Scholar
• Chandrasekar PH. Antifungal resistance in Aspergillus. Med Mycol 2005; 43(Suppl. 1)S295–2988
   Google Scholar
• Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999; 12: 501–517
   PubMed Web of Science ®Google Scholar
• Sanglard D, Odds FC. Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences. Lancet Infect Dis 2002; 2: 73–85
   PubMed Web of Science ®Google Scholar
• Pinjon E, Moran GP, Jackson CJ, et al. Molecular mechanisms of itraconazole resistance in Candida dubliniensis. Antimicrob Agents Chemother 2003; 47: 2424–2437
   PubMed Web of Science ®Google Scholar
• Favre B, Didmon M, Ryder NS. Multiple amino acid substitutions in lanosterol 14α-demethylase contribute to azole resistance in Candida albicans. Microbiology 1999; 145: 2715–2725
   PubMed Web of Science ®Google Scholar
• Slaven JW, Anderson MJ, Sanglard D, et al. Fungal increased expression of a novel Aspergillus fumigatus ABC transporter gene, atrF, in the presence of itraconazole in an itraconazole resistant clinical isolate. Fungal Genet Biol 2002; 36: 199–206
   PubMed Web of Science ®Google Scholar
• da Silva Ferreira ME, Capellaro JL, et al. In vitro evolution of itraconazole resistance in Aspergillus fumigatus involves multiple mechanisms of resistance. Antimicrob Agents Chemother 2004; 48: 4405–4413
   PubMed Web of Science ®Google Scholar
• Guerra TM, Mellado E, Cuenca-Estrella M, et al. A point mutation in the 14-alpha sterol demethylase gene cyp51A contributes to itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 2003; 47: 1120–1124
   PubMed Web of Science ®Google Scholar
• Mann PA, Parmegiani RM, Wei SQ, et al. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14-alpha demethylase. Antimicrob Agents Chemother 2003; 47: 577–581
   PubMed Web of Science ®Google Scholar
• Nascimento AM, Goldman GH, Park S, et al. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob Agents Chemother 2003; 47: 1719–1726
   PubMed Web of Science ®Google Scholar
• Mellado E, Garcia-Effron G, Alcazar-Fuoli L, et al. Substitutions at methionine 220 in the 14-alpha sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob Agents Chemother 2004; 48: 2747–2750
   PubMed Web of Science ®Google Scholar
• Mellado E, Diaz-Guerra TM, Cuenca-Estrella M, et al. Identification of two different 14-α sterol demethylase-related genes (cyp51A and cyp51B) in Aspergillus fumigatus and other Aspergillus species. J Clin Microbiol 2001; 39: 2431–2438
   PubMed Web of Science ®Google Scholar
• Mellado E, Garcia-Effron G, Buitrago MJ, et al. Targeted gene disruption of the 14-alpha sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility. Antimicrob Agents Chemother 2005; 49: 2536–2538
   PubMed Web of Science ®Google Scholar
• Katz ME, Dougall AM, Weeks K, et al. Multiple genetically distinct groups revealed among clinical isolates identified as atypical Aspergillus fumigatus. J Clin Microbiol 2005; 43: 551–555
   PubMed Web of Science ®Google Scholar
• Wang L, Yokoyama K, Miyaji M, Nishimura K. Mitochondrial cytochrome b gene analysis of Aspergillus fumigatus and related species. J Clin Microbiol 2000; 38: 1352–1358
   PubMed Web of Science ®Google Scholar
• Hong SB, Cho HS, Shin HD, et al. Novel Neosartorya species isolated from soil in Korea. Int J Syst Evol Microbiol 2006; 56: 477–486
   PubMed Web of Science ®Google Scholar
• Varga J, Vida Z, Toth B, Debets F, Horie Y. Phylogenetic analysis of newly described Neosartorya species. Antonie Van Leeuwenhoek 2000; 77: 235–239
   PubMed Web of Science ®Google Scholar
• Varga J, Rigo K, Toth B, et al. Evolutionary relationships among Aspergillus species producing economically important mycotoxins. Food Technol Biotechnol 2003; 41: 29–36
   Web of Science ®Google Scholar
• Lonial S, Williams L, Carrum G, et al. Neosartorya fischeri: an invasive fungal pathogen in an allogeneic bone marrow transplant patient. Bone Marrow Transplant 1997; 19: 753–755
   PubMed Web of Science ®Google Scholar
• Jarv H, Lehtmaa J, Summerbell RC, et al. Isolation of Neosartorya pseudofischeri from blood: first hint of pulmonary Aspergillosis. J Clin Microbiol 2004; 42: 925–928
   PubMed Web of Science ®Google Scholar
• Padhye AA, Godfrey JH, Chandler FW, et al. Osteomyelitis caused by Neosartorya pseudofischeri. J Clin Microbiol 1994; 32: 2832–2836
   PubMed Web of Science ®Google Scholar
• Guarro J, Kallas EG, Godoy P, et al. Cerebral aspergillosis caused by Neosartorya hiratsukae, Brazil. Emerg Infect Dis 2002; 8: 989–991
   PubMed Web of Science ®Google Scholar
• Balajee SA, Gribskov J, Brandt M, et al. Mistaken identity: Neosartorya pseudofischeri and its anamorph masquerading as Aspergillus fumigatus. J Clin Microbiol 2005; 43: 5996–5999
   PubMed Web of Science ®Google Scholar